Drug Profile
Epoetin beta - Roche
Alternative Names: BM 06019; NeoRecormon; r-HuEPO - Roche; Recormon; RO 205 3859Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Wyeth
- Developer Roche
- Class Antianaemics; Colony-stimulating factors; Recombinant erythropoietins
- Mechanism of Action Erythropoiesis stimulants; Erythropoietin receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Anaemia
Most Recent Events
- 02 May 2007 Results from the GAIN study added to the Haematological Disorders therapeutic trials section
- 19 Jul 2006 Results from a clinical trial (ACORD) in patients with early renal anaemia have been added to the adverse events section
- 20 Jun 2006 Results from the NAUTICA trial in cancer patients with anaemia have been added to the Haematological Disorders therapeutic trials section